Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...

Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

On Monday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $3.96 which represents a slight increase of $0.02 or 0.51% from the prior close of $3.94. The stock opened at $4.01 and ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...

Don't Miss our Black Friday Offers: Graig Suvannavejh’s rating is based on several strategic considerations despite the recent disappointing data for Alector’s AL002. Although the Phase 2 results for ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...